نتایج جستجو برای: parp inhibitors

تعداد نتایج: 192891  

Journal: :Proceedings of the National Academy of Sciences of the United States of America 2001
T Akiyama S Takasawa K Nata S Kobayashi M Abe N J Shervani T Ikeda K Nakagawa M Unno S Matsuno H Okamoto

The regeneration of pancreatic islet beta cells is important for the prevention and cure of diabetes mellitus. We have demonstrated that the administration of poly(ADP-ribose) synthetase/polymerase (PARP) inhibitors such as nicotinamide to 90% depancreatized rats induces islet regeneration. From the regenerating islet-derived cDNA library, we have isolated Reg (regenerating gene) and demonstrat...

2011
Dannis G. van Vuurden Esther Hulleman Olga L.M. Meijer Laurine E. Wedekind Marcel Kool Hendrik Witt Peter W. Peter Vandertop Thomas Würdinger David P. Noske Gertjan J.L. Kaspers Jacqueline Cloos

Poly ADP-ribose polymerase (PARP) is a protein involved in single strand break repair. Recently, PARP inhibitors have shown considerable promise in the treatment of several cancers, both in monotherapy and in combination with cytotoxic agents. Synthetic lethal action of PARP inhibitors has been observed in tumors with mutations in double strand break repair pathways. In addition, PARP inhibitio...

2015
Lars M Wagner

Inhibition of poly(ADP-ribose) polymerase (PARP) is an attractive therapeutic strategy because of the importance of this pathway in restoring DNA damage. Small-molecule inhibitors of PARP appear most effective when used to treat tumors with underlying defects in DNA repair, or when combined with DNA-damaging agents. Veliparib is one of several recently developed oral inhibitors of PARP currentl...

Journal: :Cancer research 2010
Natalia Issaeva Huw D Thomas Tatjana Djureinovic Janneke E Jaspers Ivaylo Stoimenov Suzanne Kyle Nicholas Pedley Ponnari Gottipati Rafal Zur Kate Sleeth Vicky Chatzakos Evan A Mulligan Cecilia Lundin Evgenia Gubanova Ariena Kersbergen Adrian L Harris Ricky A Sharma Sven Rottenberg Nicola J Curtin Thomas Helleday

Familial breast and ovarian cancers are often defective in homologous recombination (HR) due to mutations in the BRCA1 or BRCA2 genes. Cisplatin chemotherapy or poly(ADP-ribose) polymerase (PARP) inhibitors were tested for these tumors in clinical trials. In a screen for novel drugs that selectively kill BRCA2-defective cells, we identified 6-thioguanine (6TG), which induces DNA double-strand b...

Journal: :Annals of oncology : official journal of the European Society for Medical Oncology 2016
S B Kaye

For several years, a major obstacle in the systemic treatment of ovarian cancer has been the lack of a therapeutic strategy tailored to specific biomarkers present in the individual patient's tumour. However, considerable progress has been made recently through the development of drugs targeting cells deficient in the key mechanism of double-strand DNA repair, known as homologous recombination ...

2015
Luca Livraghi Judy E. Garber

Poly(ADP-ribose) polymerases (PARP) are enzymes involved in DNA-damage repair. Inhibition of PARPs is a promising strategy for targeting cancers with defective DNA-damage repair, including BRCA1 and BRCA2 mutation-associated breast and ovarian cancers. Several PARP inhibitors are currently in trials in the adjuvant, neoadjuvant, and metastatic settings for the treatment of ovarian, BRCA-mutated...

Journal: :Molecular cancer therapeutics 2010
Dana A Löser Atsushi Shibata Akiko K Shibata Lisa J Woodbine Penny A Jeggo Anthony J Chalmers

As single agents, chemical inhibitors of poly(ADP-ribose) polymerase (PARP) are nontoxic and have clinical efficacy against BRCA1- and BRCA2-deficient tumors. PARP inhibitors also enhance the cytotoxicity of ionizing radiation and alkylating agents but will only improve clinical outcomes if tumor sensitization exceeds effects on normal tissues. It is unclear how tumor DNA repair proficiency aff...

2013
María Isabel Rodríguez Andreína Peralta-Leal Francisco O'Valle José Manuel Rodriguez-Vargas Ariannys Gonzalez-Flores Jara Majuelos-Melguizo Laura López Santiago Serrano Antonio García de Herreros Juan Carlos Rodríguez-Manzaneque Rubén Fernández Raimundo G. del Moral José Mariano de Almodóvar F. Javier Oliver

PARP inhibition can induce anti-neoplastic effects when used as monotherapy or in combination with chemo- or radiotherapy in various tumor settings; however, the basis for the anti-metastasic activities resulting from PARP inhibition remains unknown. PARP inhibitors may also act as modulators of tumor angiogenesis. Proteomic analysis of endothelial cells revealed that vimentin, an intermediary ...

Journal: :Investigative ophthalmology & visual science 2009
Viktor R Drel Weizheng Xu Jie Zhang Peter F Kador Tayyeba K Ali Jeho Shin Ulrich Julius Barbara Slusher Azza B El-Remessy Irina G Obrosova

PURPOSE This study evaluated the role for poly(ADP-ribose) polymerase (PARP) in diabetes-induced cataractogenesis and early retinal changes. METHODS Control and streptozotocin (STZ)-diabetic rats were treated with or without the PARP inhibitors 1,5-isoquinolinediol (ISO; 3 mg kg(-1) d(-1) intraperitoneally) and 10-(4-methyl-piperazin-1-ylmethyl)-2H-7-oxa-1,2-diaza-benzo[de]anthracen-3-1 (GPI-...

2004
D. Threadgill Placido Bramanti Angelina De Sarro Christoph Thiemermann Salvatore Cuzzocrea

Poly(ADP-ribose) polymerase, (PARP), a nuclear enzyme activated by strand breaks in DNA, plays an important role in the tissue injury associated with stroke and neurotrauma. The aim of our study was to evaluate the therapeutic efficacy of in vivo inhibition of PARP in an experimental model of spinal cord trauma, which was induced by the application of vascular clips (force of 24 g) to the dura ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید